Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs ProShares Ultra QQQ ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while ProShares Ultra QQQ ETF trades at $90.62 (market cap $15.24B). The key difference: ProShares Ultra QQQ ETF is the larger of the two by market cap, and ProShares Ultra QQQ ETF is more actively traded (2,898,706 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| KYMR | QLD | |
|---|---|---|
Market Cap | $8.88B | $15.24B |
Volume | 1,028,790 | 2,898,706 |
Sector | Health | Leveraged / Inverse |
52-Week High | $127.31 | $100.77 |
52-Week Low | $55.80 | $57.16 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $8.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QLD (ProShares Ultra QQQ ETF) trades at $96.42, down 0.68% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, positioning it as a less volatile alternative to triple-leveraged products during market downturns. Recent institutional buying by 180 Wealth Advisors LLC increased their position by 29.4% in Q2 2026, signaling confidence in the fund's strategy.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $95-$97 and resistance at $98-$99. While leveraged ETFs offer amplified returns, they carry elevated risk from daily rebalancing and market volatility. Investors should monitor Fed policy impacts and tech sector momentum for directional cues, with the current setup favoring tactical positions above key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
